Skip to main content

Sources last read

Report-stream question · eight GLP-1 brands

Does a GLP-1 injection hurt?

For some GLP-1 brands far more than others. Injection site pain is 11% of everything filed about Trulicity, the highest of the 8 brands here. For Ozempic the term does not reach the stored list at all.

Source: FDA side-effect reports, read 2026-08-17

The gap is large enough to survive the caution this data needs. Trulicity’s measured share is several times the ceiling on every product where the term is missing. The ordering is not an artifact of where the list was cut.

None of this says how much it hurts, or how long. A report records that somebody named the pain, not what it felt like.

Across FDA reports

Products in the table

8

Carrying the term

5

Known only as a ceiling

3

Highest — Trulicity

11%

Which products have FDA reports for injection site pain

The same term across all eight brands. Rybelsus is in it on purpose. It is a tablet, so it cannot produce an injection site report at all. Its row shows what the method does when the true answer is already known.

◆ injection site pain — share of each product’s own reportsShare of that product’s reports
8Exact values — 8 rows in the data table
injection site pain — share of each product’s own reports
ProductShare of that product’s reports
Trulicitydulaglutide11% of Trulicity reports
Mounjarotirzepatide9.8% of Mounjaro reports
Zepboundtirzepatide6.8% of Zepbound reports
Wegovysemaglutide2.8% of Wegovy reports
Ozempicsemaglutidebelow 2.3% of Ozempic reports
Rybelsussemaglutidebelow 2.1% of Rybelsus reports
Saxendaliraglutidebelow 1.9% of Saxenda reports
Victozaliraglutide1.9% of Victoza reports

Hatched, open-ended bars are ceilings rather than measurements. Read from FDA on 2026-08-17.

A dashed row is not a zero. The snapshot keeps each product’s 25 most-reported terms, so a term missing from that list was either never reported or reported and ranked 26th. All this page can prove is that it sits at or below the 25th, and that is what the row says.

Every share above is a share of that product’s own reports. It is never a share of the people who took it, because nobody knows how many that is. Two products can differ here for reasons that have nothing to do with either drug.

The split is by product, not by needle

The four brands at the top all deliver a larger volume or a stickier solution than the ones at the bottom. Two are tirzepatide, one is dulaglutide, and the semaglutide pens sit far below them.

Wegovy and Ozempic make the point sharply. They are the same molecule from the same company, and Wegovy carries a measured share while Ozempic’s is below its own cut-off. Whatever separates them is not the drug substance.

The tablet behaves exactly as it should. Rybelsus has no measured injection site row, which is what a term that cannot physically happen looks like in this method. That is worth more than it sounds: it shows the missing rows are behaving, not hiding something.

Why a missing row is not the same as none

A missing row means the term sits below that product’s 25th most-reported, and nothing more. For Rybelsus the true count is almost certainly zero, and the method still cannot say so.

A top-25 snapshot cannot rank the four brands at the bottom. Their missing rows only mean that pain fell below each product’s reporting cut-off.

Technique is the other unknown. Where a person injects, how cold the liquid is and how fast it goes in all change how a shot feels. None of that is in a report count.

What the labels say about it

Every injectable label lists injection-site reactions as a group rather than counting pain alone. FDA reports and product labels are therefore measuring different things.

That grouping is why this page exists. A label row saying reactions where you inject were common tells you the category was seen in a trial. It does not tell you that one product collects five times the share of pain reports that another does.

This section summarizes reports people filed. The label guides show what the FDA-approved prescribing information lists. The two answer different questions and they often disagree, which is the most useful thing about having both.

What this page does and does not establish

The claims worth making are narrower than the table looks, and the narrow ones are the ones that hold.

Each claim a reader might take from this page, and what the sources behind it actually support.
The claimWhat the evidence shows
Some GLP-1 products collect far more pain reports than othersEstablished. The top measured share clears the ceiling on every product whose row is a bound.
Ozempic hurts less than MounjaroNot established as a pain rate. FDA data only shows that pain makes up a smaller share of Ozempic reports.
The four brands with no measured row can be rankedNot established. Their shares are all below their own cut-offs, which is not enough to order them.
The tablet produces no injection reportsTrue by construction, not by measurement. It is in the table as a check on the method.

Common questions

Which GLP-1 hurts least?

These reports cannot tell us which GLP-1 hurts least. Four products fall below their own reporting cut-offs, so the data cannot rank them.

Is a sore spot afterwards normal?

Reactions where you inject are on every one of these labels, so they are a known and listed thing. Whether yours is one of them is a question for a pharmacist or a clinician who can look at it.

Does the needle size explain the difference?

Not from this data. The snapshot records a term and a count, with nothing about the needle, the volume or the person. Any mechanism here would be a story laid over the numbers.

Where to go next

This page is one question asked of one snapshot. The pages below answer the neighboring ones from the labels and the trials, which is a different kind of evidence.

Every question in this section is listed on the report-stream questions index.

Read this before quoting anything above

These are counts of reports filed with the FDA, not rates. Nobody knows how many people took the drug and did not file a report, and a report is not a finding that the drug caused what was reported.

  • There is no denominator. FAERS counts reports that were filed. It does not count the people who took the drug, so there is no bottom half to the fraction. Any figure on this page that looks like a percentage is a share of this drug’s reports — never a share of the people who took it.
  • A report is not proof the drug did it. FDA does not require a reporter to establish cause. A report says somebody noticed something and thought the drug was worth naming. Some of these events were caused by the drug, some were caused by the illness it was prescribed for, and some were coincidence — FAERS does not separate them.
  • A bigger number can just mean a more-prescribed drug. More reports can simply mean that more people use the drug, that it is newer, or that it receives more news and legal attention. Raw report totals do not tell you which drug is safer.
  • The same event can be counted twice. One event can reach FAERS through more than one channel — the patient, the prescriber and the manufacturer can all file. FDA does not guarantee that the public files are de-duplicated.
  • FDA’s own words. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
  • Retrieved 2026-08-17 from https://api.fda.gov/drug/event.json · FDA data last updated 2026-07-30 · license https://open.fda.gov/license/

How everything on this site is sourced →

10primary sources, each with the day we read it — open the documents used on this page